Search the Epitope Variant and Escape Mutation Database

Help

Found 1 matching record:

Displaying record number 56141

HXB2 Location Gag(151-159) Gag Epitope Map
View variants at this location

TLNAWVKVV

`TLNAWVKVi`		diminished response
`TLNAWVKaV`		susceptible form
`TLNAWVKai`		susceptible form

Epitope Name TV9

Species (MHC/HLA) human, transgenic mouse(A2)

Variant Details

Showing all: 3 variant(s).

Variant ID.	`80`
Epitope Seq.	`TLNAWVKVV`
Variant Seq.	`TLNAWVKVi`
Mutations	V/I
Epitope Location	V9I
HXB2 Location	V159I
Mutation Type	DR: diminished response
Method	CD8 T-cell Elispot - IFNy, Chromium-release assay
Note	To identify immunogenically optimized epitopes for use in vaccines, mutants of TV9 were tested in transgenic mice. Natural TV9 mutants tested in transgenic HLA-A*02 mice showed the following responses - the common mutant V9I, TLNAWVKVi was less immunogenic and had low cross-reactivity. TLNAWVKaV (most cross-reactive) and TLNAWVKai were highly immunogenic and cross-reactive to the consensus.

Variant ID.	`81`
Epitope Seq.	`TLNAWVKVV`
Variant Seq.	`TLNAWVKaV`
Mutations	V/A
Epitope Location	V8A
HXB2 Location	V158A
Mutation Type	SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Chromium-release assay
Note	To identify immunogenically optimized epitopes for use in vaccines, mutants of TV9 were tested in transgenic mice. Natural TV9 mutants tested in transgenic HLA-A*02 mice showed the following responses - the common mutant V9I, TLNAWVKVi was less immunogenic and had low cross-reactivity. TLNAWVKaV (most cross-reactive) and TLNAWVKai were highly immunogenic and cross-reactive to the consensus.

Variant ID.	`82`
Epitope Seq.	`TLNAWVKVV`
Variant Seq.	`TLNAWVKai`
Mutations	V/A V/I
Epitope Location	V8A V9I
HXB2 Location	V158A V159I
Mutation Type	SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Chromium-release assay
Note	To identify immunogenically optimized epitopes for use in vaccines, mutants of TV9 were tested in transgenic mice. Natural TV9 mutants tested in transgenic HLA-A*02 mice showed the following responses - the common mutant V9I, TLNAWVKVi was less immunogenic and had low cross-reactivity. TLNAWVKaV (most cross-reactive) and TLNAWVKai were highly immunogenic and cross-reactive to the consensus.

References

Blondelle2008 Sylvie E. Blondelle, Rosa Moya-Castro, Keiko Osawa, Kim Schroder, and Darcy B. Wilson. Immunogenically Optimized Peptides Derived from Natural Mutants of HIV CTL Epitopes and Peptide Combinatorial Libraries. Biopolymers, 90(5):683-694, 2008. PubMed ID: 18481808. Show all entries for this paper.